Soligenix

Soligenix LT Debt/Equity

The Long-Term Debt to Equity Ratio of Soligenix (SNGX) as of Oct 17, 2026 is 0.40. In the previous year, Long-Term Debt to Equity Ratio was 0.92 — a change of -56.40% (lower).

LT Debt/Equity

0.40

YoY

-56.40%

Last updated:

Long-Term Debt to Equity Ratio of Soligenix is 2023 0.40 . Long-Term Debt to Equity Ratio of Soligenix was 2022 0.92 . It decreases by -56.40% lower compared to the previous year.

The Soligenix LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2014
0.00 USD
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
2.69 USD
Jan 1, 2021
0.92 USD
Jan 1, 2023
0.40 USD
The Soligenix LT Debt/Equity history
YEARLT Debt/EquityYoY
0.40-56.40%
0.92-65.84%
2.69+63,666.55%
0.00—
0.00—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

Long-Term Debt to Equity Ratio of Soligenix is 0.40 in 2023.

Long-Term Debt to Equity Ratio of Soligenix changed from 0.92 to 0.40, representing a -56.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Soligenix since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Soligenix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Soligenix

All Key Metrics — Soligenix